Feature

Research Reports

Costs of Extended Use of the Immune Checkpoint Inhibitors in First-line Non-Small Cell Lung Cancer

12/15/2021

Helmy M Guirgis, MD, PhD, aimed to examine cost of extended immune checkpoint inhibitor use beyond their indications in advanced/metastatic non-small cell lung cancer.

Helmy M Guirgis, MD, PhD, aimed...

12/15/2021

Journal of Clinical Pathways

Special Article

Recommendations for Enhancing the Value of Clinical Pathways: Findings From the 2020 Care Pathways Working Group

11/16/2021

Winston Wong , PharmD;

Vasily Belozeroff , PhD;

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Experts identified concerns related to care pathways and their implementation that need to be addressed in order to promote high-quality pathways that offer utility in payer negotiation, reduce costs, and reduce unnecessary variation in care...

Experts identified concerns...

11/16/2021

Journal of Clinical Pathways

Research Reports

A Value-Based Collaborative Care Model by Payers, Providers, and Pharma

10/27/2021

Lili Brillstein , MPH;

Michael Udwin , MD, FACOG;

Donna Finale ;

J Clin Pathways. 2021;7(7):22-29. doi:10.25270/jcp.2021.09.2 Received April 7, 2021; Accepted July 19, 2021.

J Clin Pathways....

10/27/2021

Journal of Clinical Pathways

Research Reports

Potential Cost Effectiveness of FES-PET to Determine Estrogen Receptor Status in Metastatic Breast Cancer in the United States

10/20/2021

Hannah M. Linden , MD;

Poorni M. Manohar , MD;

Josh A. Roth , PhD, MHA;

Poorni M. Manohar, MD, et al assessed the potential value of 18-F 16 alpha-fluoroestradiol positron emission tomography (FES-PET) vs biopsy to determine estrogen receptor status and guide therapy selection in metastatic breast cancer.

Poorni M. Manohar, MD, et al...

10/20/2021

Journal of Clinical Pathways

From the Field

Referral Patterns and Treatment Preferences in Patients With Advanced Prostate Cancer: Differences Between Medical Oncologists and Urologists

10/20/2021

Skyler Hime Rupard , MS;

Ajeet Gajra , MD, FACP;

Yolaine J. Jeune-Smith , PhD;

Bruce A. Feinberg , DO;

Ajeet Gajra, MD, FACP, et al assessed the differences between medical oncologists and urologists regarding perceptions on timing of referral and treatment sequence decisions for patients with advanced prostate cancer

Ajeet Gajra, MD, FACP, et al...

10/20/2021

Journal of Clinical Pathways

Research Reports

Patterns and Predictors of Treatment Choice in a Real-World Cohort of Patients with Metastatic Gastric Cancer in the United States

09/22/2021

Sui Zhang , MS, MPP;

Astra M. Liepa , PharmD;

Lisa M. Hess , PhD;

Gary Meyer , PhD;

Thomas A. Abrams , MD;

Peter C. Enzinger , MD;

Jeffrey A. Meyerhardt , MD, MPH;

Charles S. Fuchs ;

Deborah Schrag , MD, MPH;

Yajun Zhu , MS;

Thomas A. Abrams, MD, and colleagues examine patterns of systemic therapy administration in metastatic gastric cancer and the predictors associated with specific treatment choices.

Thomas A. Abrams, MD, and...

09/22/2021

Journal of Clinical Pathways

Research Reports

Treatment and Outcomes Among Hospitalized COVID-19 Patients With Immune-mediated Inflammatory Diseases: An Electronic Health Record Database Cohort Study

08/20/2021

Christopher D. Pericone , PhD;

Kimberly Woodruff , PharmD, PhD;

Emily S. Brouwer , MPH, PharmD, PhD;

Alex Z. Fu , PhD;

Qian Cai , MSPH, MS;

Alex Z Fu, PhD, and colleagues explore treatment journeys and outcomes for hospitalized COVID-19 patients with rheumatoid arthritis, psoriatic arthritis, psoriasis, Crohn's disease, or ulcerative colitis.

Alex Z Fu, PhD, and colleagues...

08/20/2021

Journal of Clinical Pathways

From the Field

Anticipated Cost Savings with Alternate Dosing Schema of Nivolumab/Ipilimumab for the Treatment of Metastatic Melanoma

08/20/2021

Laura Alwan , PharmD;

Evan Hall , MD;

Kate Trieselmann , PharmD;

Allison Kupsh , PharmD;

Eve Segal , PharmD;

Allison Kupsh, PharmD, and colleagues found that the anticipated cost of NIVO3+IPI1 for the treatment of metastatic melanoma may be lower compared when compared with NIVO1+IPI3, amounting to over $1,000,000 in total savings.

Allison Kupsh, PharmD, and...

08/20/2021

Journal of Clinical Pathways

Research Reports

Effectiveness of Eribulin in Metastatic Breast Cancer Patients With Poor Prognostic Indicators in the United States

06/21/2021

Bruce A. Feinberg , DO;

Talia Miller , MSW, MPH;

Jingchuan Zhang , PhD;

Marjorie E. Zettler , PhD, MPH;

Sarah S. Mougalian , MD;

A retrospective real-world study demonstrates the clinical effectiveness of eribulin in subgroups of MBC patients with poor prognostic characteristics, when used in accordance with the approved US indication.

A retrospective real-world study...

06/21/2021

Journal of Clinical Pathways

Research Reports

US Value-Based Management of Oncology Drugs: An Explorative Study of Payer and Provider Tools to Manage the Rising Spending on Oncology Drugs

06/21/2021

Oliver Walker , PhD;

Daniele Severi-Bruni , MS;

Anne Runyan , BA;

Kolajo Salako , BS;

Anne Runyan, BA , and colleagues point out that, despite increasing cancer costs in the United States, payers’ willingness and ability to manage oncology drugs remains limited.

Anne Runyan, BA , and colleagues...

06/21/2021

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Feature

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products